vs

Side-by-side financial comparison of EMPIRE PETROLEUM CORP (EP) and Immunovant, Inc. (IMVT). Click either name above to swap in a different company.

Immunovant, Inc. is the larger business by last-quarter revenue ($8.4M vs $7.1M, roughly 1.2× EMPIRE PETROLEUM CORP). EMPIRE PETROLEUM CORP runs the higher net margin — -835.1% vs -899.0%, a 63.9% gap on every dollar of revenue. On growth, Immunovant, Inc. posted the faster year-over-year revenue change (140.7% vs -30.0%).

The Iraq Petroleum Company (IPC), formerly known as the Turkish Petroleum Company (TPC), is an oil company that had a virtual monopoly on all oil exploration and production in Iraq between 1925 and 1961. It was jointly owned by some of the world's largest oil companies and headquartered in London, England.

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapies for patients with serious, rare autoimmune and inflammatory diseases. Its lead product candidate covers multiple autoimmune indications, with core U.S. operations and a global market expansion strategy.

EP vs IMVT — Head-to-Head

Bigger by revenue
IMVT
IMVT
1.2× larger
IMVT
$8.4M
$7.1M
EP
Growing faster (revenue YoY)
IMVT
IMVT
+170.8% gap
IMVT
140.7%
-30.0%
EP
Higher net margin
EP
EP
63.9% more per $
EP
-835.1%
-899.0%
IMVT

Income Statement — Q4 FY2025 vs Q4 FY2024

Metric
EP
EP
IMVT
IMVT
Revenue
$7.1M
$8.4M
Net Profit
$-59.0M
$-75.3M
Gross Margin
Operating Margin
-834.5%
-896.2%
Net Margin
-835.1%
-899.0%
Revenue YoY
-30.0%
140.7%
Net Profit YoY
-1306.0%
-26.7%
EPS (diluted)
$-1.74
$-0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EP
EP
IMVT
IMVT
Q4 25
$7.1M
Q3 25
$9.4M
Q2 25
$8.8M
Q1 25
$9.0M
Q4 24
$10.1M
Q3 24
$11.4M
Q2 24
$12.8M
Q1 24
$9.4M
$8.4M
Net Profit
EP
EP
IMVT
IMVT
Q4 25
$-59.0M
Q3 25
$-3.8M
Q2 25
$-5.1M
Q1 25
$-4.2M
Q4 24
$-4.2M
Q3 24
$-3.6M
Q2 24
$-4.4M
Q1 24
$-4.0M
$-75.3M
Operating Margin
EP
EP
IMVT
IMVT
Q4 25
-834.5%
Q3 25
-37.8%
Q2 25
-56.0%
Q1 25
-43.9%
Q4 24
-38.9%
Q3 24
-30.0%
Q2 24
-15.0%
Q1 24
-46.8%
-896.2%
Net Margin
EP
EP
IMVT
IMVT
Q4 25
-835.1%
Q3 25
-40.9%
Q2 25
-57.8%
Q1 25
-46.9%
Q4 24
-41.6%
Q3 24
-32.0%
Q2 24
-34.3%
Q1 24
-42.3%
-899.0%
EPS (diluted)
EP
EP
IMVT
IMVT
Q4 25
$-1.74
Q3 25
$-0.11
Q2 25
$-0.15
Q1 25
$-0.12
Q4 24
$-0.12
Q3 24
$-0.12
Q2 24
$-0.15
Q1 24
$-0.15
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EP
EP
IMVT
IMVT
Cash + ST InvestmentsLiquidity on hand
$1.2M
$635.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$-4.6M
$617.8M
Total Assets
$65.9M
$666.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EP
EP
IMVT
IMVT
Q4 25
$1.2M
Q3 25
$4.6M
Q2 25
$2.3M
Q1 25
$1.1M
Q4 24
$2.3M
Q3 24
$3.1M
Q2 24
$9.3M
Q1 24
$3.5M
$635.4M
Total Debt
EP
EP
IMVT
IMVT
Q4 25
Q3 25
$15.2M
Q2 25
$14.6M
Q1 25
$11.6M
Q4 24
$11.3M
Q3 24
$8.5M
Q2 24
$8.5M
Q1 24
$8.5M
Stockholders' Equity
EP
EP
IMVT
IMVT
Q4 25
$-4.6M
Q3 25
$53.7M
Q2 25
$54.5M
Q1 25
$59.1M
Q4 24
$62.8M
Q3 24
$56.5M
Q2 24
$58.7M
Q1 24
$31.7M
$617.8M
Total Assets
EP
EP
IMVT
IMVT
Q4 25
$65.9M
Q3 25
$123.0M
Q2 25
$124.7M
Q1 25
$123.7M
Q4 24
$123.9M
Q3 24
$121.2M
Q2 24
$119.9M
Q1 24
$100.1M
$666.4M
Debt / Equity
EP
EP
IMVT
IMVT
Q4 25
Q3 25
0.28×
Q2 25
0.27×
Q1 25
0.20×
Q4 24
0.18×
Q3 24
0.15×
Q2 24
0.15×
Q1 24
0.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EP
EP
IMVT
IMVT
Operating Cash FlowLast quarter
$-2.8M
$-59.7M
Free Cash FlowOCF − Capex
$-59.8M
FCF MarginFCF / Revenue
-714.4%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-214.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EP
EP
IMVT
IMVT
Q4 25
$-2.8M
Q3 25
$330.0K
Q2 25
$-3.1M
Q1 25
$1.6M
Q4 24
$-8.8M
Q3 24
$12.8M
Q2 24
$-1.8M
Q1 24
$3.9M
$-59.7M
Free Cash Flow
EP
EP
IMVT
IMVT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$-59.8M
FCF Margin
EP
EP
IMVT
IMVT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-714.4%
Capex Intensity
EP
EP
IMVT
IMVT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
1.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons